Literature DB >> 22137486

A complex MLL rearrangement identified five years after initial MDS diagnosis results in out-of-frame fusions without progression to acute leukemia.

Claus Meyer1, Eric Kowarz, Sze-Fai Yip, Thomas Shek-Kong Wan, Tai-Kwong Chan, Theo Dingermann, Li-Chong Chan, Rolf Marschalek.   

Abstract

Chromosomal rearrangements of the MLL gene are uncommon in myelodysplastic syndromes (MDSs), and few studies of their molecular structures and oncogenic mechanisms exist. Here, we present a case of de novo MDS with a normal karyotype at initial diagnosis and a mild clinical course. Five years after the initial diagnosis, investigators identified a complex rearrangement of the MLL gene without progression to acute leukemia. The 5' part of the MLL gene is fused out of frame with the LOC100131626 gene, and the 3' part of the MLL gene out of frame with the TCF12 gene. Rapid amplification of complementary DNA 3' ends yielded two main fusion transcripts, which is in concordance with the two described isoforms of the LOC100131626 gene. For both isoform-fusion transcripts, the open reading frame terminates shortly after the breakpoint that is predicted to form two de facto truncated MLL proteins and disrupts the open reading frame of the LOC100131626, TCF12, and UBE4A genes. Neither dimerization nor a transcriptional activation domain, each of which is causally linked to MLL protein-mediated transformation, is present. This and other unusual MLL rearrangements probably represent a subclass of MLL gene abnormalities that have intrinsically no ability or only a weak ability to transform hematopoeitic cells and are identified only in the context of other hematopoetic malignancies.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22137486     DOI: 10.1016/j.cancergen.2011.10.001

Source DB:  PubMed          Journal:  Cancer Genet


  5 in total

1.  Co-existence of a novel translocation t(11;22)(q23;q12.1) with PML-RARA in acute promyelocytic leukemia: a case report.

Authors:  Woo Yong Shin; Jung-Ah Kim; Seug Yun Yoon; Hae In Bang; Jong-Ho Won; Ho Hyun Song; Jieun Kim; Rojin Park
Journal:  Ann Hematol       Date:  2022-07-02       Impact factor: 4.030

2.  AucPR: an AUC-based approach using penalized regression for disease prediction with high-dimensional omics data.

Authors:  Wenbao Yu; Taesung Park
Journal:  BMC Genomics       Date:  2014-12-12       Impact factor: 3.969

Review 3.  Cancer cytogenetics: methodology revisited.

Authors:  Thomas S K Wan
Journal:  Ann Lab Med       Date:  2014-10-28       Impact factor: 3.464

4.  The MLL recombinome of acute leukemias in 2017.

Authors:  C Meyer; T Burmeister; D Gröger; G Tsaur; L Fechina; A Renneville; R Sutton; N C Venn; M Emerenciano; M S Pombo-de-Oliveira; C Barbieri Blunck; B Almeida Lopes; J Zuna; J Trka; P Ballerini; H Lapillonne; M De Braekeleer; G Cazzaniga; L Corral Abascal; V H J van der Velden; E Delabesse; T S Park; S H Oh; M L M Silva; T Lund-Aho; V Juvonen; A S Moore; O Heidenreich; J Vormoor; E Zerkalenkova; Y Olshanskaya; C Bueno; P Menendez; A Teigler-Schlegel; U Zur Stadt; J Lentes; G Göhring; A Kustanovich; O Aleinikova; B W Schäfer; S Kubetzko; H O Madsen; B Gruhn; X Duarte; P Gameiro; E Lippert; A Bidet; J M Cayuela; E Clappier; C N Alonso; C M Zwaan; M M van den Heuvel-Eibrink; S Izraeli; L Trakhtenbrot; P Archer; J Hancock; A Möricke; J Alten; M Schrappe; M Stanulla; S Strehl; A Attarbaschi; M Dworzak; O A Haas; R Panzer-Grümayer; L Sedék; T Szczepański; A Caye; L Suarez; H Cavé; R Marschalek
Journal:  Leukemia       Date:  2017-07-13       Impact factor: 11.528

5.  t(15;21) translocations leading to the concurrent downregulation of RUNX1 and its transcription factor partner genes SIN3A and TCF12 in myeloid disorders.

Authors:  Alberto L'Abbate; Doron Tolomeo; Francesca De Astis; Angelo Lonoce; Crocifissa Lo Cunsolo; Dominique Mühlematter; Jacqueline Schoumans; Peter Vandenberghe; Achilles Van Hoof; Orazio Palumbo; Massimo Carella; Tommaso Mazza; Clelia Tiziana Storlazzi
Journal:  Mol Cancer       Date:  2015-12-16       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.